FERNANDO GOLDSZTEIN
Fernando Goldsztein has a BA in Business from PUCRS and an MBA at MIT Sloan School of Management. He is partner and Board Member of Cyrela. Moved by the most difficult experience for a parent - hearing from a doctor that their child cannot be cured - he made a decision to make the fight against child cancer the purpose of his life. This is the story of The Medulloblastoma Initiative. He is also a Board Member of Childrens National Foundation in Washington D.C.
Check the activity agenda
Monday, March 23, 2024
• Room 3
13:30-15:30
SESSION 4: PRESENT - FUTURE
Is proton beam therapy a real deal in pediatric neurooncology?
Pre-clinical studies in medulloblastoma: what is new?
Genetic Predisposition Syndromes: How new molecular technologies can help us in the diagnosis and treatment
When does Precision Medicine make a difference in the treatment of our pediatric patients with brain tumors?
The Medulloblastoma initiative-
Liquid biopsy for pediatric neurooncology tumors. Is it possible?
Study Protocol and Perspectives: Embryonal Tumors in infants
Discussion
Moderator: Gabriela Bellas (RJ)
Moderator: Maria Luisa Sucharski Figueiredo (Brasil)
Is proton beam therapy a real deal in pediatric neurooncology?
Speaker: Michael Jenwei Chen (SP)
Pre-clinical studies in medulloblastoma: what is new?
Speaker: Carolina Nör (Estados Unidos)
Genetic Predisposition Syndromes: How new molecular technologies can help us in the diagnosis and treatment
Speaker: Fernanda Teresa de Lima (SP)
When does Precision Medicine make a difference in the treatment of our pediatric patients with brain tumors?
Speaker: Elvis Terci Valera (SP)
The Medulloblastoma initiative-
Speaker: Fernando Goldsztein (RS)
Liquid biopsy for pediatric neurooncology tumors. Is it possible?
Speaker: Liana Figueiredo Nobre (Canadá)
Study Protocol and Perspectives: Embryonal Tumors in infants
Speaker: Natália Dassi (SP)
Discussion
Promoted by
Organization
Tourism agency
SILVER SPONSOR
BRONZE SPONSOR
SUPPORT SPONSOR
Institutional Support
